Skip to main content

Table 3 HRQL impact of psoriasis at Week 16: study population versus general US population

From: Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

  Adalimumab Mean (SD)1 Placebo Mean (SD)2 General US Population3 Mean (SD)
Physical Functioning 51.3(9.0) 48.6 (10. 4) 49.4 (10.0)
Role-Physical 52.3(8.4) 49.4 (10.6) 50.1 (9.9)
Bodily Pain 54.3(9.3) 48.9 (10.9) 49.2 (10.2)
General Health 51.8(8.6) 50.2 (9.3) 49.3 (10.7)
Vitality 53.2(9.2) 50.5 (10.4) 50.4 (10.5)
Social Functioning 51.4(8.5) 47.2 (10.9) 50.1 (10.1)
Role-Emotional 51.3(8.9) 48.3 (11.8) 50.6 (9.5)
Mental Health 51.1(9.2) 49.1 (11.0) 49.4 (10.7)
  1. 1N = 774–775.
  2. 2N = 354.
  3. 3SF-36 values for males and females aged 45 to 54 years from SF-36 manual (1998 population); N = 417.